Search the Newsreel

Plato Investment Management Ltd Makes New $11.95 Million Investment in Citigroup Inc. $C

Plato Investment Management Ltd has made a new investment of $11.95 million in Citigroup Inc., purchasing 85,879 shares in the second quarter. This move makes Citigroup the 27th largest holding in Plato's portfolio, comprising 0.7% of their total investments. Institutional investors now collectively own …

Diamond Hill Capital Management LLC Investment Advisor Invests $52.94 Million in Citigroup Inc. $C

Diamond Hill Capital Management LLC Investment Advisor recently acquired a new stake in Citigroup Inc. (NYSE:C) during the second quarter, purchasing 378,238 shares valued at approximately $52.94 million. Other institutional investors have also adjusted their holdings in Citigroup, reflecting varied sentiment. The article details …

Citius Pharmaceuticals GAAP EPS of -$0.34 misses by $0.09, revenue of $1.5M misses by $8.27M

* Citius Pharmaceuticals press release [https://seekingalpha.com/pr/20620155-citius-pharmaceuticals-inc-reports-fiscal-third-quarter-2026-financial-results-and-provides] (CTXR [https://seekingalpha.com/symbol/CTXR]): Q3 GAAP EPS of -$0.34 misses by $0.09. * Revenue of $1.5M misses by $8.27M. * Cash and cash equivalents of $17.0 million as of June 30, 2026. MORE ON CITIUS PHARMACEUTICALS * Seeking Alpha’s Quant …

S&CO Inc. Buys New Shares in Citigroup Inc. $C

S&CO Inc. has acquired 39,794 shares of Citigroup Inc. (NYSE:C) in the second quarter, valued at approximately $5.57 million, increasing institutional ownership to 71.72%. Citigroup recently reported strong quarterly earnings, beating estimates with an EPS of $3.15 and revenue of $24.77 billion, and authorized …

Citizens & Northern Corp Takes Position in Wells Fargo & Company $WFC

Citius Pharmaceuticals Reports LYMPHIR Revenue Growth, Explores CAR-T Combination

Citius Pharmaceuticals reported promising early results for its approved drug LYMPHIR in new indications, including an 86% objective response rate in a Phase 1 CAR-T combination trial for diffuse large B-cell lymphoma and a 24% ORR in gynecologic malignancies. The company also announced strong …

Diversified Banks Stocks Q2 Earnings: Citigroup (NYSE:C) Firing on All Cylinders

Diversified Banks Stocks Q2 Earnings: Citigroup (NYSE:C) Firing on All Cylinders As the Q2 earnings season comes to a close, it's time to take stock of this quarter's best and worst performers in the diversified banks industry, including Citigroup (NYSE:C) and its peers. At …

Citizens, Inc. president & CEO Jon Stenberg buys $43,795 in stock

Citizens, Inc. President and CEO Jon Stenberg recently purchased 12,000 shares of the company's Class A Common Stock for $43,795, reflecting increased executive ownership. This transaction occurred on August 11, 2026, with shares bought at $3.6496 each, near its 52-week low. InvestingPro analysis suggests …

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. (NASDAQ:CTOR) is anticipated to reach profitability by 2027, according to analysts, after posting a significant loss in its most recent financial year. The company is projected to achieve a profit of US$12 million in 2027, driven by an estimated annual growth …

Assenagon Asset Management S.A. Has $1.18 Million Stock Position in First Citizens BancShares, Inc. $FCNCA

Citizens & Northern (NASDAQ:CZNC) Upgraded to Strong-Buy at Wall Street Zen

Wall Street Zen upgraded Citizens & Northern (NASDAQ:CZNC) to a "strong-buy" rating. This follows other upgrades from Weiss Ratings and Zacks Research, although the overall analyst consensus remains "Hold" with a $23.50 target price. The company recently reported strong quarterly earnings of $0.79 per …

Citizens Community Bancorp, Inc. (NASDAQ:CZWI) Given Average Recommendation of "Hold" by Brokerages

Citizens & Northern (NASDAQ:CZNC) Stock Passes Above 200-Day Moving Average - Should You Sell?

Citizens & Northern (NASDAQ:CZNC) stock recently surpassed its 200-day moving average, trading as high as $26.25, significantly above its long-term average of $22.76. Despite improved analyst sentiment and recent upgrades, the consensus rating remains "Hold" with a target price below the current share price. …

Wall Street Zen Downgrades Citizens Community Bancorp (NASDAQ:CZWI) to Sell

Citizens (NYSE:CIA) Rating Lowered to Strong Sell at Wall Street Zen

Citigroup Global Markets (GSAT) schedules NASDAQ sale of 24,100 common shares

Citigroup Global Markets Inc. has filed to sell up to 24,100 common shares of Globalstar, Inc. (GSAT) on NASDAQ, with an aggregate market value of $1,980,352.43. The sale is scheduled for on or after August 14, 2026. The filing also details prior restricted stock …

Citius Oncology (NASDAQ:CTOR) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Citius Oncology (NASDAQ:CTOR) reported its quarterly earnings, missing analyst expectations with an EPS loss of $0.08 against an estimated $0.07, and revenue of $1.49 million, below the $2.50 million estimate. Despite the misses, the stock price rose 10% to $0.91 on Friday with double …

Citius Oncology (CTOR) director Jonathan Peri files Form 3 showing no common shares

Citigroup (C) Agrees To Acquire A Rewards Startup

Citigroup (NYSE:C) is set to acquire rewards startup Kard Financial to enhance its consumer engagement capabilities. Concurrently, Citi is involved in financing major U.S. power infrastructure projects, aligning its strategy with both next-generation consumer rewards and large-scale infrastructure finance. These initiatives support Citi's focus …

Citius Pharmaceuticals Reports Q3 2026 Financial Results and LYMPHIR Progress

Citius Pharmaceuticals reported strong Q3 2026 financial results, including $7.1 million in commercial sales revenue for the first nine months of the fiscal year and $17 million in cash reserves. The company highlighted significant progress with its lead product, LYMPHIR, noting an 86% objective …

Citius Oncology (CTOR) grows LYMPHIR sales but posts $41M nine-month loss

Citius Oncology's LYMPHIR has 44 ordering institutions, 383 July vials

Divisadero Street group (CTRN) discloses 705,451 Citi Trends shares, 8.5% ownership

Divisadero Street Capital Management, LP and related entities have disclosed beneficial ownership of 705,451 shares of Citi Trends Inc. common stock, which represents an 8.5% stake in the company as of June 30, 2026. The filing indicates shared voting and dispositive power over these …

Citius Pharmaceuticals (CTXR) holders report 3.0M-share, 9.9% beneficial stake

CVI Investments, Inc. and Heights Capital Management, Inc. have reported a beneficial ownership of 3,008,529 common shares in Citius Pharmaceuticals (CTXR), which represents a 9.9% stake. This position primarily consists of shares issuable upon the exercise of warrants, subject to beneficial ownership limits of …

Citigroup's Kard Acquisition Deal: A New Growth Engine for U.S. Cards?

Citigroup, Inc. C has been sharpening its focus on strengthening its U.S. consumer banking franchise, with credit cards remaining one of the company's most important customer businesses. As competition in cards increasingly shifts toward personalized rewards, digital engagement and merchant-funded offers, C has been …

Is Citigroup a Solid Investment Option After a 51.2% Jump in a Year?

Citigroup (C) shares have surged 51.2% in the past year, outperforming industry growth, driven by its ongoing overhaul plan, impressive earnings, and a simplified business structure. The company's strategic divestitures, cost optimization, and investments in technology are expected to drive revenue growth and improve …

Citizens Financial Group (NYSE:CFG) Sets New 52-Week High - Time to Buy?

Participation notifications by Citigroup Inc.

Citigroup Inc. has provided transparency notifications to Solvay S.A., indicating that its holdings crossed the 3% threshold of voting rights. The notification details that on August 11, 2026, Citigroup's total voting rights, including equivalent financial instruments, reached 3.04%. This disclosure is in compliance with …

DA Davidson reiterates Citizens Financial stock rating on growth outlook By Investing.com

DA Davidson has reiterated a Buy rating and an $85.00 price target for Citizens Financial Group (NYSE:CFG), citing strong growth prospects. The firm projects peer-leading EPS growth for Citizens Financial this year and next, supported by upward earnings revisions from analysts and various organic …

Manulife Financial (CZWI) discloses sub-5% Citizens Community Bancorp ownership

Manulife Financial Corporation, through its investment subsidiaries Manulife Investment Management (US) LLC and Manulife Investment Management Limited, has filed an amended Schedule 13G/A disclosing a beneficial ownership of less than 5% in Citizens Community Bancorp Inc. Manulife Investment Management (US) LLC holds 4.96% of …

CHINA CITIC FINANCIAL ASSET MANAGEMENT CO., LTD.

Citius Oncology (CTOR) investor reports 9.99% beneficial ownership stake

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9,353,553 shares of Citius Oncology, Inc. common stock, which represents a 9.99% stake in the company. They hold shared voting and dispositive power over these shares, which are directly held by Armistice …

CITIC Securities: The Hang Seng TECH Index is expected to undergo a significant revision, with changes to constituent stocks taking effect as early as the December index rebalancing date.